Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers.
Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers.
复制标题
DOI：
10.1158/2159-8290.cd-18-1286
复制
发表时间：
2019-01
期刊：
影响因子：
28.2
通讯作者：
Byers LA
中科院分区：
文献类型：
--
作者：
Della Corte CM;Byers LA
STK11 （LKB1）突变是非小细胞肺癌（NSCLC）免疫治疗原发性耐药的主要原因。Barbie及其同事剖析了这种免疫抗性表型的潜在机制，证明LKB1缺失直接导致STING抑制和对细胞质双链DNA （dsDNA）检测不敏感。重新激活LKB1或STING途径的疗法可能会增强对免疫检查点阻断有抵抗力的癌症的抗癌免疫反应。
Mutations in STK11 (LKB1) are a major cause of primary resistance to immunotherapy in non-small cell lung cancer (NSCLC). Barbie and colleagues dissect the underlying mechanism of this immune-resistant phenotype, demonstrating that LKB1 loss leads directly to suppression of STING and insensitivity to cytoplasmic double strand DNA (dsDNA) detection. Therapies that re-activate LKB1 or the STING pathway may boost anti-cancer immune response in cancers with resistance to immune checkpoint blockade.